| pubmed-article:1330665 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1330665 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:1330665 | lifeskim:mentions | umls-concept:C0330390 | lld:lifeskim |
| pubmed-article:1330665 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:1330665 | lifeskim:mentions | umls-concept:C2330894 | lld:lifeskim |
| pubmed-article:1330665 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1330665 | pubmed:dateCreated | 1992-12-18 | lld:pubmed |
| pubmed-article:1330665 | pubmed:abstractText | Beta-adrenergic receptors on cultured human retinal pigment epithelium were demonstrated by the binding of [125I]cyanopindolol. Its pharmacologic specificity was also examined. Specific [125I]cyanopindolol binding was saturable, with a dissociation constant of 130 pM and a receptor density of 12 fmol per one-half million cells, which is equivalent to 14,000 receptor sites per retinal pigment epithelial cell. Agonists competed for specific [125I]cyanopindolol binding, with the following rank order of potencies: (-)-isoproterenol > (-)-epinephrine > (-)-norepinephrine. Beta 2-selective antagonist ICI-118551 was approximately 3 log orders more potent than the beta 1-selective antagonist, betaxolol. These receptors were also coupled to an adenylate cyclase. These results suggest strongly that cultured human retinal pigment epithelial cells possess beta 2-adrenergic receptors. The potential significance of these findings with regard to retinal pigment epithelial functions is discussed herein. | lld:pubmed |
| pubmed-article:1330665 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1330665 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1330665 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1330665 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1330665 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:1330665 | pubmed:issn | 0014-4835 | lld:pubmed |
| pubmed-article:1330665 | pubmed:author | pubmed-author:TranV TVT | lld:pubmed |
| pubmed-article:1330665 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1330665 | pubmed:volume | 55 | lld:pubmed |
| pubmed-article:1330665 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1330665 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1330665 | pubmed:pagination | 413-7 | lld:pubmed |
| pubmed-article:1330665 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:meshHeading | pubmed-meshheading:1330665-... | lld:pubmed |
| pubmed-article:1330665 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1330665 | pubmed:articleTitle | Human retinal pigment epithelial cells possess beta 2-adrenergic receptors. | lld:pubmed |
| pubmed-article:1330665 | pubmed:affiliation | Department of Ophthalmology, University of Southern California School of Medicine, Los Angeles. | lld:pubmed |
| pubmed-article:1330665 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1330665 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1330665 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
